Last reviewed · How we verify

NCT05206474: IRADYN

To Evaluate the Performance and Safety of the Medical Device IRADYN in Subjects With Osteoarthritis of the Knee

Status unknown NA Last updated 15 March 2022
What this trial tests

NA trial testing IRADYN in Knee Osteoarthritis in 50 participants. Status unknown.

Timeline
7 March 2022
Primary endpoint
1 August 2022
1 October 2022

Quick facts

Lead sponsorI.R.A. Istituto Ricerche Applicate S.p.A.
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment50
Start date7 March 2022
Primary completion1 August 2022
Estimated completion1 October 2022
Sites2 locations across Romania

Drugs / interventions tested

Conditions studied

Sponsor

I.R.A. Istituto Ricerche Applicate S.p.A.

Who can join

Adults 40 to 80, any sex, with Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The benefits of single or repetitive administration (1 to 6) can have similar result in terms of muscular strength and patients' quality of life improvement, benefiting of the advantages of polymerized polynucleotides (IRADYN) formulation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Knee Osteoarthritis

Currently open trials in the same condition.

Other I.R.A. Istituto Ricerche Applicate S.p.A. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05206474.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing